Bone metabolic disease is a systemic bone metabolic disease, an important reason for the high fracture rate and high mortality of the elderly and brings a heavy economic burden to society. Bone remodeling mainly involves osteoclast resorption and osteoblast bone formation in a continuous alternation. Bone homeostasis can be compromised when there is an imbalance between resorption and formation. This occurs in common bone diseases such as osteoporosis, hyperparathyroidism, renal osteodystrophy, Paget’s disease, and metastatic bone disease. Therefore, it has become an urgent problem to find safe and effective drugs to treat bone metabolic diseases and explore the pharmacological mechanism affecting bone formation and bone absorption.
Bone homeostasis is strictly regulated by the balanced activity of osteoblasts and osteoclasts. Disruption of the balance of activity between osteoblasts and osteoclasts leads to various metabolic bone diseases. Clinical and basic research on bone metabolic diseases has progressed very rapidly. Phytochemicals with therapeutic and preventive effects against bone resorption and promote bone formation have recently received increasing attention since they are potentially more suitable for long-term use than traditional therapeutic chemical compounds. However, the pharmacological mechanism of these drugs' influence on bone formation and bone resorption remains unclear. It has become a research frontier in this field. This Research Topic aims to actively explore the relationship between bone formation and bone resorption, discover new drugs to treat bone metabolic diseases, and study the pharmacological mechanism of drugs affecting bone formation and resorption.
We welcome submissions of original research papers and review articles in the following sub-topics, including but not limited to outgoing studies, reviews, systematic reviews, and meta-analyses.
• A new mechanism of drug intervention in bone metabolism from the perspective of stem cells
• Specific drug therapy and molecular mechanisms for bone metabolic disease
• Effects of traditional Chinese medicine or its active components on bone formation and bone resorption
• Immunomodulation of bone metabolism and pharmacological mechanisms of drugs
• Explain the pharmacological mechanisms of drug interventions on the bone formation or bone resorption from the perspective of aging
• The coupling of osteoblasts, osteoclasts, and osteocytes and the mechanism of drug influence
Frontiers in Experimental Pharmacology and Drug Discovery does not accept for publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
This applies also to reviews, perspective, opinion.
This applies also to in silico studies on supposed mechanisms underlying supposed actions of crude extracts and/or mixtures.
Whenever a complex mixture is used, data with the single components of the mixture, in precisely defined dose/concentration, should be provided (and/or previously published). Studies including traditional Chinese medicine remedies can be considered only if carried out with pure individual compounds.
Bone metabolic disease is a systemic bone metabolic disease, an important reason for the high fracture rate and high mortality of the elderly and brings a heavy economic burden to society. Bone remodeling mainly involves osteoclast resorption and osteoblast bone formation in a continuous alternation. Bone homeostasis can be compromised when there is an imbalance between resorption and formation. This occurs in common bone diseases such as osteoporosis, hyperparathyroidism, renal osteodystrophy, Paget’s disease, and metastatic bone disease. Therefore, it has become an urgent problem to find safe and effective drugs to treat bone metabolic diseases and explore the pharmacological mechanism affecting bone formation and bone absorption.
Bone homeostasis is strictly regulated by the balanced activity of osteoblasts and osteoclasts. Disruption of the balance of activity between osteoblasts and osteoclasts leads to various metabolic bone diseases. Clinical and basic research on bone metabolic diseases has progressed very rapidly. Phytochemicals with therapeutic and preventive effects against bone resorption and promote bone formation have recently received increasing attention since they are potentially more suitable for long-term use than traditional therapeutic chemical compounds. However, the pharmacological mechanism of these drugs' influence on bone formation and bone resorption remains unclear. It has become a research frontier in this field. This Research Topic aims to actively explore the relationship between bone formation and bone resorption, discover new drugs to treat bone metabolic diseases, and study the pharmacological mechanism of drugs affecting bone formation and resorption.
We welcome submissions of original research papers and review articles in the following sub-topics, including but not limited to outgoing studies, reviews, systematic reviews, and meta-analyses.
• A new mechanism of drug intervention in bone metabolism from the perspective of stem cells
• Specific drug therapy and molecular mechanisms for bone metabolic disease
• Effects of traditional Chinese medicine or its active components on bone formation and bone resorption
• Immunomodulation of bone metabolism and pharmacological mechanisms of drugs
• Explain the pharmacological mechanisms of drug interventions on the bone formation or bone resorption from the perspective of aging
• The coupling of osteoblasts, osteoclasts, and osteocytes and the mechanism of drug influence
Frontiers in Experimental Pharmacology and Drug Discovery does not accept for publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
This applies also to reviews, perspective, opinion.
This applies also to in silico studies on supposed mechanisms underlying supposed actions of crude extracts and/or mixtures.
Whenever a complex mixture is used, data with the single components of the mixture, in precisely defined dose/concentration, should be provided (and/or previously published). Studies including traditional Chinese medicine remedies can be considered only if carried out with pure individual compounds.
